Secondary Logo

Journal Logo

July/August 2022 - Volume 42 - Issue 4

  • Anthony J. Rothschild, MD
  • 0271-0749
  • 1533-712X
  • 6 issues / year
  • Psychiatry 101/155; Pharmacy and Pharmacology 170/279
  • 3.118

Photo -AJ Rothschild, MD in front of medical school.jpgWelcome to the July/August 2022 issue of the Journal of Clinical Psychopharmacology. There are many fascinating and thought-provoking articles in this issue. I would like to highlight a few of them. On pages 340-342, Drs. Baldessarini and Vázquez have written a thoughtful and balanced review of the recent book, The Rise and Fall of the Age of Psychopharmacology, by historian Edward Shorter. They provide the reader with a concise summary of this 431-page nonstop criticism of modern clinical psychopharmacology. In my Editorial on page 339, I offer my perspective of the book and why the book ignores the fact that many people with serious psychiatric disorders have had their lives dramatically improved by psychotropic medications. I also found that the one mention of JCP in the book was factually inaccurate. The Editorial is accompanied by a podcast. We are also pleased to announce that this year's winner of the Mitchell B. Balter Award is an article by Dr. Simon Alfred Handley, Dr. Susanna Every-Palmer, and, Dr. Robert James Flanagan entitled, “Antipsychotic-Related Fatal Poisoning, England and Wales, 1993–2019: The Impact of Second-Generation Antipsychotics."  It was published in the Journal in the November/December 2021 issue. This annual award was established in memory of Mitchell B. Balter, PhD, to recognize reports of outstanding investigation on topics related to Dr Balter's research in pharmacoepidemiology. On page 344, Associate Editor Dr. Susan McElroy has written an In Memoriam on the passing of Dr. Charles Bowden. Grover and colleagues, in a paper entitled, “Factors Associated With Poor Response to Clozapine in Schizophrenia" (pp. 345-349) report that clozapine nonresponders, although broadly similar in sociodemographic profile to clozapine responders, differ from clozapine responders on past treatment profile. Finally, on pages 391-395, Béchard and colleagues in their paper entitled, “Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series" present data on clozapine rechallenge after agranulocytosis and conclude that it may be less perilous than first thought, but that a systematic review on this specific subject is needed. There is also an accompanying podcast by Dr. Béchard. And as you will see, there are many other interesting Original Contributions, Brief Reports, and Letters to the Editor in the July/August 2022 issue! 

 Anthony J. Rothschild, MD


Current Issue Highlights

Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series

Béchard, Laurent; Morasse-Bégis, Mahité; Corbeil, Olivier; More

Journal of Clinical Psychopharmacology. 42(4):391-395, July/August 2022.

Duration: 9:40

Clozapine is often prescribed for patients with treatment-resistant schizophrenia, but its use is sometimes discontinued if it is suspected of inducing neutropenia. In this podcast, author Laurent Béchard discusses a consecutive case series published in the July-August 2022 issue of the Journal of Clinical Psychopharmacology assessing the continuation or reintroduction of this drug despite a neutropenia episode. In addition to suggesting further research to better define severe vs. moderate cases, Dr. Béchard proposes the use of pharmacovigilance tools to assess possible causes of neutropenia so clinicians can better determine if this highly effective antipsychotic should remain part of a patient’s treatment plan.